The single dose pharmacokinetics and saf
โ
Harri Kanerva; Olavi Kilkku; Esa Heinonen; Antti Helminen; Juha Rouru; Simo Tarp
๐
Article
๐
1999
๐
John Wiley and Sons
๐
English
โ 201 KB
๐ 2 views
The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg